Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.
about
Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routesInduction of intestinal immunity by mucosal vaccines as a means of controlling HIV infectionA review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccineOral vaccination: where we are?Formulations containing poly(lactide-co-glycolide) and plasmid DNA expression vectors.Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.Purification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaquesApproaches to enhance the efficacy of DNA vaccines.Technologies for enhanced efficacy of DNA vaccines.Microparticles for the delivery of DNA vaccines.Mucosal AIDS vaccines: current status and future directions.T-cell-biased immune responses generated by a mucosally targeted adenovirus-σ1 vaccineOrally delivered malaria vaccines: not too hard to swallow.Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules.Delivery systems and adjuvants for oral vaccines.Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvantPolymeric nano- and microparticle technologies for oral gene delivery.Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag.Combined vaccine regimen based on parenteral priming with a DNA vaccine and administration of an oral booster consisting of a recombinant Salmonella enterica serovar Typhimurium vaccine strain for immunization against infection with human-derived enProgress towards a needle-free hepatitis B vaccine.Enhancing efficacy and mucosa-tropic distribution of an oral HIV-PsV DNA vaccine in animal models.Construction of sperm-specific lactate dehydrogenase DNA vaccine and experimental study of its immunocontraceptive effect on mice.Chitosan-zein nano-in-microparticles capable of mediating in vivo transgene expression following oral delivery.DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration.HIV infection and specific mucosal immunity: workshop 4B.Oral plasmid DNA delivery systems for genetic immunisation.Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo.Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
P2860
Q22241377-1BB54C62-37D3-4A2A-9EBB-6B84C5EE72B6Q27001897-49815612-77A9-4B8B-A118-145AD1105962Q30431343-5AB9AAFA-A04F-40AF-AC2A-9D57B30B09B4Q34343918-BD758981-04C1-4AED-8853-D7E67CECBECEQ34660422-C7B6B81A-41F0-4B46-BA54-6CF4586616E1Q35207503-FEC52AF4-6587-4E54-B3ED-A1758E548CD1Q35413374-9B7B067C-FDA8-4D92-9FA2-ED20374CFC88Q35732677-BCF8BD03-98F8-4F53-84CF-1C0B86B35602Q35743279-2DCA138C-3D0A-48BC-85C6-C5E2E85C1185Q35802958-EA115F1A-209D-40B5-852E-F847C0CD8A5FQ35826399-8B35C9EF-D553-472E-9670-267AFC1842BCQ35851782-C59E72DF-3847-41B3-8753-4412B0B4F32CQ35894806-11D98C1B-0456-4FA5-A307-94548CAACFD8Q35907014-E0DF3016-C90F-443B-8AE7-5C0A1B8FE467Q36427024-2B492F42-69EA-49B0-A8E4-3DFCA52DE37DQ36640326-3BB8DE10-F541-435B-8F2E-6CD77C37D57AQ36694830-D8D2EAF1-5E67-4D2B-B4BB-5384538C7C4FQ36815912-0B806123-9632-40F1-987A-AFE4D8772F89Q36819089-A863D8BA-119B-49D1-860A-DEF34C903B2AQ37511451-24286C5C-4779-4DBB-AF4D-23B6F2ACFD23Q37582794-DE79CAD1-DAC5-4976-87BE-6D141DFEF1A7Q37810816-4FEEA9E3-573F-4BD9-B6C4-F0409397B60AQ39013219-4B566B6C-9C19-4BF5-82CC-53D923A26278Q40110116-87C70EA7-5FAF-447D-AA42-E47E4D9F233DQ40353194-82B23BA9-E786-46B2-A3F9-D8E129E64D07Q40587927-D45E389F-50DF-4D49-BFA4-07FCC369AF9BQ43994786-86CC20EC-D682-431A-84DB-07B894D30995Q44941797-15E98BF5-F38B-4736-B25B-FA58FC1FFD10Q45889163-D6280192-FA1A-4B45-96B0-EBF70C17D6D7Q52558317-0BCB60FB-AE4D-4F54-8020-D17D938C8DB7
P2860
Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Oral DNA vaccination promotes ...... to HIV envelope glycoprotein.
@en
Oral DNA vaccination promotes ...... to HIV envelope glycoprotein.
@nl
type
label
Oral DNA vaccination promotes ...... to HIV envelope glycoprotein.
@en
Oral DNA vaccination promotes ...... to HIV envelope glycoprotein.
@nl
prefLabel
Oral DNA vaccination promotes ...... to HIV envelope glycoprotein.
@en
Oral DNA vaccination promotes ...... to HIV envelope glycoprotein.
@nl
P2093
P356
P1433
P1476
Oral DNA vaccination promotes ...... to HIV envelope glycoprotein.
@en
P2093
Bednarek I
Dmochowski M
Wierzbicki A
P356
10.1006/VIRO.1999.0093
P407
P577
2000-02-01T00:00:00Z